Mai Guan Fu Kang capsule attenuates coronary heart disease via PI3K/Akt signaling pathway and gut microbiota.
H, S., Z, S., X, W., L, D., F, B., Y, S., D, Y., H, S., J, L., & Y, X. (2026). Mai Guan Fu Kang capsule attenuates coronary heart disease via PI3K/Akt signaling pathway and gut microbiota.. The Journal of pharmacy and pharmacology. https://doi.org/10.1093/jpp/rgag039
H S, Z S, X W, L D, F B, Y S, et al. Mai Guan Fu Kang capsule attenuates coronary heart disease via PI3K/Akt signaling pathway and gut microbiota.. The Journal of pharmacy and pharmacology. 2026; doi: 10.1093/jpp/rgag039
H S, Z S, X W, et al. Mai Guan Fu Kang capsule attenuates coronary heart disease via PI3K/Akt signaling pathway and gut microbiota.[J]. The Journal of pharmacy and pharmacology. 2026. DOI: 10.1093/jpp/rgag039.
@article{h2026,
author = {Shangguan H and Sun Z and Wang X and Ding L and Bai F and Sun Y and Yang D and Shi H and Liu J and Xie Y},
title = {Mai Guan Fu Kang capsule attenuates coronary heart disease via PI3K/Akt signaling pathway and gut microbiota.},
journal = {The Journal of pharmacy and pharmacology},
year = {2026},
doi = {10.1093/jpp/rgag039},
note = {PMID: 42234811},
}
TY - JOUR AU - Shangguan H AU - Sun Z AU - Wang X AU - Ding L AU - Bai F AU - Sun Y AU - Yang D AU - Shi H AU - Liu J AU - Xie Y TI - Mai Guan Fu Kang capsule attenuates coronary heart disease via PI3K/Akt signaling pathway and gut microbiota. T2 - The Journal of pharmacy and pharmacology PY - 2026 DO - 10.1093/jpp/rgag039 AN - PMID:42234811 ER -
OBJECTIVE: To investigate the therapeutic mechanism of Mai Guan Fu Kang Capsule (MGFKC) against coronary heart disease (CHD). METHODS: MGFKC constituents were identified by liquid chromatography-mass spectrometry (LC-MS). Network pharmacology predicted bioactive compounds, targets, and CHD-associated targets. Protein-protein interaction networks were constructed, followed by Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment analyses. A CHD animal model was used to assess myocardial histopathology, serum biomarkers, inflammatory cytokines, oxidative stress, PI3K/Akt signaling pathway protein expression, gut microbiota, and short-chain fatty acids (SCFAs) metabolism. KEY FINDINGS: Key active components included salvianolic acid B and luteolin. Network analysis indicated involvement of the PI3K/Akt signaling pathway. MGFKC alleviated myocardial injury and histopathological changes, suppressed inflammation and oxidative stress, and regulated PI3K/Akt protein expression. It also ameliorated gut microbiota dysbiosis and restored SCFAs metabolism. CONCLUSION: MGFKC exerts multi-target effects against CHD through synergistic regulation of the PI3K/Akt pathway, providing anti-inflammatory, antioxidant, and anti-apoptotic activities. Improvement of gut microbiota and SCFAs metabolism further contributes to its cardioprotective mechanism.